Staying the same

Mometasone to remain a mostly prescription product after downscheduling application is knocked back TGA regulators have rejected a proposal to move the corticosteroid mometasone to become a Schedule 3 product. It was decided that diagnosis, management and monitoring of the medical condition was such that it required medical intervention before mometasone was used. Mometasone remains